about
Comparative in silico analyses and experimental validation of novel splice site and missense mutations in the genes MLH1 and MSH2.Genomic profiling by DNA amplification of laser capture microdissected tissues and array CGHChromosomal instability in MYH- and APC-mutant adenomatous polyps.GENETICS. The Human Variome ProjectThe CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype.Preventive surgery for colon cancer in familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer syndrome.Frequency and spectrum of cancers in the Peutz-Jeghers syndrome.Cross-species comparison of human and mouse intestinal polyps reveals conserved mechanisms in adenomatous polyposis coli (APC)-driven tumorigenesis.Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis.How to catch all those mutations--the report of the third Human Variome Project Meeting, UNESCO Paris, May 2010.Clinical implications of molecular diagnosis in hereditary nonpolyposis colorectal cancer.Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients.Gender-Specific Aspects of Lynch Syndrome and Familial Adenomatous Polyposis.Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European expertsPrevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma/carcinoma prevention programme 2.Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous PolyposisLynch syndrome: clinical, pathological, and genetic insights.Surgical considerations in FAP-related pouch surgery: Could we do better?Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database.Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome databaseColorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report.
P50
Q30379599-AC25CBF7-2292-493E-9E68-9669FBDB26A5Q33208489-87E3760A-BF35-47C8-83E6-2F9F29D83A64Q33235184-B50C7EE4-8E36-433F-B3D1-191FE9E022CDQ33608598-1059DDBE-25DA-4B0A-86DB-1392865E5A03Q33904762-800C08F7-9503-40EA-820E-696AC8FF04C7Q34190072-0C2123B2-0F05-4818-9F31-2DABC2137874Q34567595-FA91E71F-8717-4396-AC66-8A14F44A5FF0Q34769120-0CC4D64A-B0C1-4128-B236-70018248A47DQ34901055-6FDB3E10-AAA0-4709-AC75-40CC74E2F55DQ34974010-3FFC3948-CC71-4F67-8FE0-DAA50ED27CE3Q35058184-4346C626-29B6-4CD1-A59C-A93088856359Q35146987-0103BC92-AAEB-4006-A626-CD8F4A63FF8DQ35746793-0AE25027-8896-4DB2-BAA6-65405F44FAE7Q35885813-D248C48C-C335-45DF-B6D8-E1C66D660D6DQ36824964-55990403-8100-49C7-8F1A-8C71656A6B94Q37103047-EEB51B17-FFFF-4E22-BF3F-C1D272E78D51Q37153032-A14678A5-C6D7-45B4-ABC0-697F0DE4886AQ37987828-E894B612-3211-4566-8645-44B5DBB1FFCCQ38838016-A3001138-8ADA-47ED-B360-2E893020D29BQ40221041-1A00ED3B-2151-4865-8981-A46D1985D5D7Q40719336-7662405C-F9F3-4980-AE46-2FDE6828B156Q42374502-1FB5BD0C-4CEE-452C-A520-81B992172C12
P50
description
onderzoeker
@nl
name
Gabriela Möslein
@ast
Gabriela Möslein
@en
Gabriela Möslein
@es
Gabriela Möslein
@nl
Gabriela Möslein
@sl
type
label
Gabriela Möslein
@ast
Gabriela Möslein
@en
Gabriela Möslein
@es
Gabriela Möslein
@nl
Gabriela Möslein
@sl
prefLabel
Gabriela Möslein
@ast
Gabriela Möslein
@en
Gabriela Möslein
@es
Gabriela Möslein
@nl
Gabriela Möslein
@sl